Oncolytics Biotech buy El_Zocko
Summary
This prediction ended on 16.06.15 with a price of €4.87. The prediction for Oncolytics Biotech disappointed with a performance of -27.75%. El_Zocko has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Oncolytics Biotech | - | - | - | - |
| iShares Core DAX® | -2,12 % | -7,97 % | -1,73 % | 53,34 % |
| iShares Nasdaq 100 | -1,32 % | -0,07 % | 16,60 % | 81,16 % |
| iShares Nikkei 225® | -0,32 % | -6,38 % | 25,63 % | 52,30 % |
| iShares S&P 500 | -1,57 % | -1,97 % | 10,83 % | 60,91 % |
Comments by El_Zocko for this prediction
In the thread Oncolytics Biotech diskutieren
Runde 2 im Zock - ONCOLYTICS BIOTECH
Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.
Quelle: http://www.oncolyticsbiotech.com/


